This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WCG, CL, SJM, PRX Hit 52-Week Highs

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Par Pharmaceutical

"We see Par as well positioned to expand upon its relatively niche position in a very healthy US generic market with the recent Anchen and Edict acquisitions," JPMorgan analysts wrote in a March 16 report. "Unlike some of its larger competitors, Par has ample opportunity, we believe, to profitably expand its US generic market share through its current product pipeline and targeted acquisitions. That said, we see growth prospects for the combined Par business in line with our generic coverage universe and a fairly balanced risk/reward for PRX shares at current levels (roughly 10x 2012E EPS)."

Shares of Par Pharmaceutical hit a 52-week high Friday of $39.42. The stock's 52-week low of $24.85 was st on Sept. 22.

Par Pharmaceutical's forward P/E is 10.07; the average for pharmaceutical companies is 22.22. For comparison, Medicis Pharmaceutical (MRX) and Vivus (VVUS) both have higher forward P/Es of 12.13 and 48.24, respectively.

Eight of the 12 analysts who cover Par Pharmaceutical rated it buy. Four analysts gave the stock a hold rating.

TheStreet Ratings gives Par Pharmaceutical a B grade with a buy rating and a $42.43 price target. The stock has risen 19.16% year to date.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CL $70.92 -0.34%
SJM $126.98 -0.63%
WCG $89.99 -2.61%
AAPL $93.74 -1.15%
FB $117.58 0.73%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs